FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	hours por rosponso:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					<u> </u>		011 00(11)	or tire	1111000	none C	ZOTTIP	July Act	01 10-0										
1. Name and Address of Reporting Person* MELLETT PAUL J						2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
					EN	ENTA]										Officer	or (give title		10% Ov Other (s	· I			
(Last) (First) (Middle)																	(give title		below)	specify			
(Last)	`	,	` ,			3. Date of Earliest Transaction (Month/Day/Year)										Treasurer and CFO							
C/O ENANTA PHARMACEUTICALS, INC.					111/	11/19/2021																	
500 ARSENAL STREET							4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable						
(Street)					7. '	4. If Amendment, Date of Original Filed (Month/Day/Year)										Line)							
, ,	ΓOWN M	T A	02472													K Form f	iled by One	ed by One Reporting Person					
			02472													Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)																				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																						
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		` c₀	Transaction Disposed Code (Instr. 5)						es Form ally (D) of Following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
										de V		Amount	(A) or (D)		Price		action(s) 3 and 4)			(Instr. 4)			
Common Stock 11/19					1/2021		A	(1)		6,800 A		\$0	56,559 ⁽²⁾			D							
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date, T	Code (In		of Derivati Securiti Acquire (A) or Dispose of (D) (II	erivative (Necurities equired) or		. Date Exercisable and xpiration Date Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	isable	Ex _I	piration te	Title	OI N Of	umber								
Stock Option (right to buy)	\$75.33	11/19/2021			A		28,400		(3	3)	11/	/19/2031	Commo Stock		8,400	\$0	28,40	0	D				

Explanation of Responses:

- 1. Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.
- 2. The amount of securities beneficially owned by the reporting person was incorrectly stated on the Form 4 filed on January 8, 2021 as "61,759" instead of "49,759." The amount of securities beneficially owned, as reported in column 5 of this Form 4, corrects this error.
- 3. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

/s/ Nathaniel S. Gardiner as 11/23/2021 attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.